🇺🇸 FDA

Company profile · Sponsor

Kura

Kura Oncology

KURA · NYSE pharma SAN DIEGO, CA, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

Kura (KURA) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker KURA
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001422143

Pipeline (24)

Search pipeline →

  1. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. Ziftomenib

    Kura

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  3. Cytarabine

    Kura

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  4. Dexamethasone

    Kura

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  5. Tipifarnib

    Kura

    HNSCC

    phase 2 small molecule completed

    1 trial

  6. Tipifarnib

    Kura

    HRAS Gene Mutation

    phase 2 small molecule completed

    1 trial

  7. Tipifarnib

    Kura

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  8. Tipifarnib

    Kura

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  9. Tipifarnib

    Kura

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  10. Tipifarnib

    Kura

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  11. Ziftomenib

    Kura

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

  12. Ziftomenib, Ziftomenib

    Kura

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Kura

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial

  14. Darlifarnib

    Kura

    Solid Tumors With HRAS Alterations

    phase 1 small molecule active

    1 trial

  15. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

  16. KO-947

    Kura

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  17. Tipifarnib

    Kura

    NSCLC

    phase 1 small molecule terminated

    1 trial

  18. Tipifarnib

    Kura

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  19. Venetoclax

    Kura

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  20. Ziftomenib

    Kura

    Relapsed/Refractory KMT2A-r Acute Leukemia

    phase 1 small molecule active

    1 trial

  21. Ziftomenib

    Kura

    AML

    phase 1 small molecule active

    1 trial

  22. Ziftomenib

    Kura

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  23. Ziftomenib

    Kura

    KMT2A-rearranged

    phase 1 small molecule active

    1 trial

  24. Ziftomenib

    Kura

    Refractory Acute Leukemia

    phase 1 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. ziftomenib

    KOMZIFTI

    ORAL approved

Patents (8)

Search patents →

  1. US 12410184

    Crystalline forms of a menin inhibitor

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12377026

    Dental adhesive material kit

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12358210

    Resin composition for stereolithography

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12344691

    Resin composition for stereolithography

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12214061

    Adhesive composition for dental use

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12208148

    Dental restorative curable composition

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12145888

    Zirconia molded body and pre-sintered body capable of being sintered in short time

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12138325

    Dental composition

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Kura?

Kura (KURA) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Kura sponsor?

We track 24 ClinicalTrials.gov-linked programs for Kura, including VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Kura company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.